AAHRPP web site

 


Definitions



A glossary of lay terms used in preparing consent forms is available [also opens in a separate window].

ASSURANCE: A formal written, binding commitment that is submitted to a federal agency in which an institution promises to comply with applicable regulations governing research with human subjects and stipulates the procedures through which compliance will be achieved.

BENEFICENCE: An ethical principle discussed in the Belmont Report that entails an obligation to protect persons from harm. The principle of beneficence can be expressed in two general rules: (1) do not harm; and (2) protect from harm by maximizing possible benefits and minimizing possible risks of harm.

BENEFIT: A valued or desired outcome; an advantage.

CLINICAL TRIAL: A controlled study involving human subjects, designed to evaluate prospectively the safety and effectiveness of new drugs or devices or of behavioral interventions.

COMPENSATION: Payment or medical care provided to subjects injured in research; does not refer to payment (remuneration) for participation in research. (Compare: Remuneration.)

CONFIDENTIALITY: Confidentiality refers to the understanding between the investigator and participant in how data will be managed and used.

CONTROL (SUBJECTS) or CONTROLS: Subject(s) used for comparison who are not given a treatment under study or who do not have a given condition, background, or risk factor that is the object of study. Control conditions may be concurrent (occurring more or less simultaneously with the condition under study) or historical (preceding the condition under study). When the present condition of subjects is compared with their own condition on a prior regimen or treatment, the study is considered historically controlled.

DEOXYRIBO-NUCLEIC ACID (DNA): Genetic material contained in cells organized in several large structures called chromosomes.

DEVICE (MEDICAL): An instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including a component part, or accessory which is: recognized in the official National Formulary, or the United States Pharmacopoeia, or any supplement to them; intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals; or intended to affect the structure or any function of the body of man or other animals, and which does not achieve any of it's primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of any of its primary intended purposes.

DRUG: Any chemical compound that may be used on or administered to humans as an aid in the diagnosis, treatment, cure, mitigation, or prevention of disease or other abnormal conditions.

FDA: Food and Drug Administration; an agency of the federal government established by Congress in 1912 and presently part of the Department of Health and Human Services.

GRANT: Financial support provided for research study designed and proposed by the principal investigator(s). The granting agency exercises no direct control over the conduct of approved research supported by a grant.

HUMAN SUBJECT RESEARCH: See Determining if Activities Meet Organizational Definition of Human Subject Research.

INVESTIGATOR: In clinical trials, an individual who actually conducts an investigation. Any interventions (e.g., drugs) involved in the study are administered to subjects under the immediate direction of the investigator. (See also: Principal Investigator.)

OFFICE FOR HUMAN RESEARCH PROTECTIONS (OHRP): The office within the Department of Health and Human Services, responsible for implementing DHHS regulations (45 CFR Part 46) governing research involving human subjects.

PRINCIPAL INVESTIGATOR: The scientist or scholar with primary responsibility for the design and conduct of a research project. (See also: Investigator.)

PRIVACY: Refers to persons and their interest in controlling access of others to themselves.

PROTOCOL DIRECTOR: The scientist or scholar with primary responsibility for the design and conduct of a research project. (See also: Investigator.)

QUALITY IMPROVEMENT ACTIVITIES: Quality improvement (QI) activities may, but do not necessarily, constitute human research. QI attempts to measure the effectiveness of programs or services, often medical services or treatment. Such activities may constitute human research, if they are designed or intended to contribute to generalizable knowledge. If they are designed solely for internal program evaluation purposes, with no intended external application or generalization, they do not require IRB review and approval (although in some cases the exempt status of the activity may need to be confirmed by the RCO).

REMUNERATION: Payment for participation in research. (NOTE: It is wise to confine use of the term "compensation" to payment or provision of care for research-related injuries.) (Compare: Compensation.)

TRANSLATOR/INTERPRETER: Person fluent in English and in the necessary second language, who can accurately speak, read, and readily interpret the necessary second language. Has the ability to translate the names of body parts and to describe competently symptoms and injuries in both languages. [California Health & Safety Code 1259 (b)(1)].

VOLUNTARY: Free of coercion, duress, or undue inducement. Used in the research context to refer to a subject's decision to participate (or to continue to participate) in a research activity.





Stanford University | Dean of Research | Research Compliance

Human Subjects Federalwide Assurance Number: FWA00000935, 8/14/2001 - 3/5/2012
Medical IRB Nos. 01, 03, 04, 05, 06, 07 & 08 Nonmedical IRB No. 02
© Stanford University. All rights reserved.
Last modified: Tuesday, 01-Jul-2008 11:14:49 PDT